摘要
树突状细胞 (DC)是目前发现功能最强的专职抗原呈递细胞 (APC) ,DC疫苗的开发研制尚处于早期阶段 ,但已获得的大量有价值的实验数据可以表明 ,DC在启动抗肿瘤免疫的抗原呈递中发挥出强大的功能。DC体外培养的方法渐趋成熟 ,提高DC生物学功效的手段多彩纷呈 ,日益增多的临床研究工作推动着该领域的迅速发展。作者就DC肿瘤疫苗制备方法及其在临床试验中的应用作一综述 ,并提出该免疫治疗中尚存在的一些问题。
A novel approach of vaccination against cancer is to exploit dendritic cells (DC) as the best antigen presenting cells (APC) and actively immunize cancer patients with a sample of autologous or allogeneic DC primed with tumor antigens. DC vaccination is still at its early stage, however, valuable proofs of concept have been obtained with respect to the capacity of DC to expand cancer directed immune responses. The methods for preparing DC are being improved continuously, and there are many opportunities to improve efficacy at the level of DC biology. An increased number of clinical studies will drive the development of this new area. This paper reviews the production of dendritic cell tumor vaccines and their use in clinical trials, as well as emphasizes some unresolved questions in this immunotherapy.
出处
《医学研究生学报》
CAS
2005年第1期63-66,70,共5页
Journal of Medical Postgraduates
基金
国家自然科学基金资助项目 (批准号 :3 0 3 3 0 610 )
